Background {#Sec1}
==========

Interstitial lung diseases (ILDs) are generally characterized by the accumulation of inflammatory cells within the lung, followed by the progressive deposition of extracellular matrix and subsequent destruction of alveolar airspaces \[[@CR1]\]. The precise role of inflammatory cells in the pathogenesis of ILD remains poorly understood \[[@CR2]--[@CR4]\], although evidence indicates that T lymphocytes play an important role in the initiation and development of pulmonary fibrosis \[[@CR5], [@CR6]\]. However, few studies evaluate the prognostic significance of T lymphocyte subsets in patients with nonspecific interstitial pneumonia (NSIP) \[[@CR7]\]. Therefore, we hypothesized that patients with NSIP who respond successfully to corticosteroid therapy harbor different T lymphocyte subpopulations compared with patients who do not respond.

To test this hypothesis, we evaluated the distribution of T lymphocyte subsets in the lung tissues of patients with NSIP. Using immunohistochemistry, we quantified the T lymphocyte subsets present in lymphoid follicles as well as in perivascular, interstitial, and peribronchial regions and explored the relationship between prognosis and survival.

Methods {#Sec2}
=======

Study subjects and diagnostic criteria {#Sec3}
--------------------------------------

Between April 2003 and December 2011, 97 patients from Peking Union Medical College Hospital (PUMCH) were diagnosed with NSIP according to analysis of lung biopsies. Fifty-five patients who completed follow-up by undergoing tests of pulmonary function tests and computed tomography (CT) of the chest were included in this study. NSIP was diagnosed according to the American Thoracic Society (ATS)/European Respiratory Society consensus classification \[[@CR8], [@CR9]\]. Patients were not treated with corticosteroids or other immunosuppressants before undergoing a lung biopsy. Connective tissue disease (CTD) was diagnosed according to the criteria of the American College of Rheumatology as follows: autoantibodies against the nucleus (ANA titer \>1:320), rheumatoid factor, Sjögren's-syndrome-related antigens SSA or SSB, Scl-70, Sm, anti-Jo-1, ribonucleoprotein, or cyclic citrullinated peptide \[[@CR10]--[@CR13]\]. Patients with NSIP were classified into the groups as follows: (1) Members of the CTD-NSIP group met the criteria of the American College of Rheumatology for CTD. (2) Members of the NSIP-Ab + group had at least one positive serologic test. (3) Members of the NSIP-Ab-- group were autoantibody negative. We extracted clinical characteristics documented at the time of a patient's first visit as follows: age, ethnicity, sex, symptoms (cough, dyspnea, or wheeze) at the time of lung biopsy, symptoms or signs of CTD, smoking status, physical examination findings, pulmonary function results, serologic results, and chest CT scan.

Informed consent to use medical records was obtained from every patient, their guardian, or both when the patient was admitted to the hospital. The PUMCH Institutional Review Board approved this study (reference number for ethics approval: 2012--10--312).

Pulmonary physiological assessments {#Sec4}
-----------------------------------

Spirometry, total lung capacity determined using plethysmography, forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide were measured according to ATS recommendations \[[@CR14]--[@CR16]\], and the results are expressed as the percentage of predicted normal values. Prognosis was described according to FVC 1 year after steroid therapy. We classified patients as follows: FVC-group 1, improvement of FVC \>10 %; FVC-group 2, improvement of FVC between 10 % and −10 %; and FVC-group 3, FVC reduced greater than −10 % \[[@CR17]--[@CR20]\].

High-resolution CT {#Sec5}
------------------

All patients underwent high-resolution CT (HRCT) of the chest upon initial evaluation. A radiologist who specializes in diffuse parenchymal lung disease reviewed the CT scans. The extent and prevalence of abnormalities were measured in the areas as follows: (1) from the lung apex to the carina, (2) from the carina to the upper pulmonary vein, and (3) from the upper pulmonary vein to the base of the lung. HRCT images were assessed to determine the extent of parenchymal abnormalities, including ground-glass opacity (GGO), reticulation, honeycombing, consolidation, and emphysema. The extent of these abnormalities was determined using a 10 % scale for six zones \[[@CR21]\]. Prognosis is described according to the manifestations detected using CT 1 year after steroid therapy. Patients with NSIP were classified as follows: CT-group 1, improvement of GGO and reticular opacity \>50 %; group, CT-group 2, lesions reduced between 30 % and 50 %, and CT-group 3, lesions reduced by \<30 % \[[@CR21]--[@CR23]\].

Histology of lung tissue {#Sec6}
------------------------

Two experienced pathologists reviewed independently the lung biopsy specimens, and the histologic pattern was assigned according to the consensus opinion. The pathologists were unaware of the patients' clinical information. The histological patterns of the 55 patients were classified further, according to criteria proposed by Katzenstein and Fiorelli \[[@CR24]\], as cellular, mixed, or fibrotic. Small airways were defined as those with an internal diameter \<2 mm without cartilage in the airway walls \[[@CR25]\]. Small blood vessels were defined as those with an internal diameter ≤100 μm \[[@CR26]\].

Immunohistochemical analysis of CD4 and CD8 expression in lung tissue {#Sec7}
---------------------------------------------------------------------

Lung biopsy specimens were fixed in 10 % neutral-buffered formalin, cut into slices, embedded in paraffin, and cut into 4-μm-thick sections. Paraffin sections were reacted anti-CD4 (clone SP35, Zeta), and anti-CD8 (clone EP1150, Zeta) antibodies using the labeled-streptavidin-biotin complex method. The sections were deparaffinized, rehydrated with Tris-Buffered Saline (TBS) (0.005 M Tris, 0.15 M NaCl, pH 7.6) for 10 min, treated with 3 % hydrogen peroxide for 5 min to inhibit endogenous peroxidase activity, washed in TBS, and incubated with primary antibodies for 1 h. Immunohistochemical analyses of CD4 and CD8 expression were performed using the same tissue sections.

The numbers of dark-brown cells were determined using a NanoZoomer 2.0-RS Slide Scanning System (Hamamatsu Photonics KK; Japan Tokyo) and an Anymicro DSS Pro Image Analysis System (Yu Tian Shi Ji Wei Ye INC; Beijing, China). The follicles as well as perivascular, interstitial, and peribronchial regions were analyzed. The images of CD4+ and CD8+ T lymphocytes were obtained from the same region of the slide. At least six high-power fields (magnification × 200; analysis area, approximately 0.162 mm^2^) were randomly selected for each region and used to count the stained cells (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Distribution of T lymphocytes in different regions of lung tissue: CD4+ and CD8 + T lymphocytes decreased gradually in order of Lymphoid follicle, perivascular, interstitial and peribronchiolar regions. Positively stained of CD4+ and CD8 + T lymphocytes with dark brown staining

Treatment and follow up {#Sec8}
-----------------------

All patients received a standard initial course of oral prednisone, starting at 0.5 mg/kg/d for 1 month that was tapered every 3 weeks to 5--7.5 mg/d (10 % decrease of the initial dose every 3 weeks), and maintained at 5--7.5 mg/d. Patients were treated for 12--18 months. Cyclophosphamide was administered concurrently with steroid therapy at an oral dose of 100 mg/d administered for 3--6 months to patients diagnosed with CTD-NSIP. Patients underwent routine examinations every 3--6 months after lung biopsy and then once each year at the Interstitial Lung Disease Clinic of PUMCH.

Statistical analysis {#Sec9}
--------------------

All values are expressed as the mean ± standard deviation (SD). Normally distributed data were evaluated using the *t* test. The Wilcoxon and Kruskal--Wallis tests were used to compare two or more non-normally distributed values, respectively. Fisher's exact test was used to determine differences between groups. Correlation coefficients were calculated using the Spearman rank method. Cox multivariate regression analysis was used to evaluate risk factors of survival. The times to overall survival were calculated using the Kaplan--Meier method. The probability value was obtained using 2-sided tests, and statistical significance was defined as *p* \< 0.05. SPSS 15.0 (SPSS for Windows, version 15.0; SPSS Inc., Chicago, IL, USA) was used for statistical analysis.

Results and discussion {#Sec10}
======================

Clinical features and laboratory findings {#Sec11}
-----------------------------------------

The clinical, radiological, and physiological measurements obtained at the time of the initial visit are shown in Table [1](#Tab1){ref-type="table"}. The mean age of 55 patients was 48.9 ± 10.5 years (range, 23--68 years), and 36 patients (65 %) were women. There were 47 nonsmokers, six former smokers, and two current smokers. The mean duration of respiratory symptoms from onset to lung biopsy was 6 months (20.2 ± 50.9 months; range, 0.8--360 months). All patients were followed for a mean duration of 64.3 ± 26.7 months (range, 14--120 months).Table 1Clinical features and laboratory findings of patients with NSIPNSIP (*n* = 55)Clinical manifestations, N (%)Dyspnea40 (72.7)Cough47(85.5)Chest pain4(7.3)Dry eyes or dry mouth3(5.5)Fever7 (12.7)Arthralgia9(16.4)Skin rash6(10.9)Raynaud's phenomenon3(5.5)Weight loss4(7.3)Crackles41(74.6)Clubbing21(38.2)Laboratory tests ESR, mm/h21.2 ± 19.2 PaO~2~, mmHg77.8 ± 12.9 PCO~2~, mmHg37.9 ± 8.4Serological results, N (%) Anti-nuclear antibody14 (25.5) Anti-SSA antibody3 (5.5) Anti-neutrophil cytoplasmic antibody3 (5.5) Anti-Jo-1 antibody1 (1.8) Anti-Scl-70 antibody1 (1.8)PFT TLC, % predicted76.8 ± 14.1 DLCO, % predicted56.4 ± 16.8Baseline chest CT findings, N (%) Ground glass opacity34 (61.8) Patchy opacity40 (72.7) Irregular reticular opacity35 (63.6) Traction bronchiectasis17 (30.9) Pleural thickness5 (14.6)

The patients were diagnosed as follows: 21 with CTD-NSIP (including seven with polymyositis/dermatomyositis; seven with rheumatoid arthritis; four with of Sjögren syndrome; two with systemic sclerosis, and one with microscopic polyangiitis), 14 with NSIP-Ab (+), and 20 with NSIP-Ab (−). There were no differences among the three groups according to age, sex, cough, and dyspnea. Symptoms of arthralgia, Raynaud's phenomenon, skin rash, and dry eye or mouth were highly associated with the CTD-NSIP and NSIP-Ab + groups compared with the NSIP-Ab- group (Table [2](#Tab2){ref-type="table"}). No differences among the three groups were noted in arterial blood gas and HRCT findings. Abnormalities of pulmonary function were similar among the three groups and were characterized by restrictive defects with impairment of diffusion (Table [3](#Tab3){ref-type="table"}). During follow-up, three patients (15 %) with cellular NSIP died (two from lung infections, one from liver failure), and six (21 %) and four (80 %) patients with mixed or fibrotic NSIP, respectively, died from progression of lung disease.Table 2Clinical features of patients classified as CTD-NSIP, NSIP-Ab (+), or NSIP-Ab (−)CharacteristicsCTD-NSIP (*n* = 21)NSIP-Ab (+) (*n* = 14)NSIP-Ab (−) (*n* = 20)*p* valueAge (years)50.48 ± 11.7344.57 ± 8.8150.50 ± 9.990.197Male (%)15/21 (71.4 %)10/14 (71.4 %)11/20 (55.0 %)0.468Duration (months)12.21 ± 18.0618.06 ± 30.9930.20 ± 78.730.528Follow-up time (months)43.14 ± 23.9053.43 ± 29.0744.40 ± 24.010.467Symptoms Dyspnea15/21 (71.4 %)13/14 (92.9 %)19/20 (95 %)0.067 Cough14/21 (66.7 %)10/14 (71.4 %)16/20 (80 %)0.627 Chest pain2/21 (9.5 %)1/14 (7.1 %)1/20 (5 %)0.856 Dry eyes or dry mouth2/21 (9.5 %)1/14 (7.1 %)00.386 Fever2/21 (9.5 %)2/14 (14.3 %)3/20 (15 %)0.853 Arthralgia6/21 (28.6 %)3/14 (21.4 %)1/20 (5 %)0.138 Rash5/21 (23.8 %)1/14 (7.1 %)00.044 Raynaud's phenomenon3/21 (14.3 %)000.077 Weight loss2/21 (9.5 %)1/14 (7.1 %)1/20 (5.0 %)0.856Signs Crackles19/21 (90.5 %)13/14 (92.9 %)15/20 (75 %)0.246 Clubbing7/21 (33.3 %)5/14 (35.7 %)5/20 (25 %)0.765Table 3Laboratory values of patients classified as CTD-NSIP, NSIP-Ab (+) and NSIP-Ab (−)Laboratory testsCTD-NSIP (*n* = 21)Ab (+)-NSIP (*n* = 14)Ab (−)-NSIP (*n* = 20)*p* valueESR, mm/h16.33 ± 7.6919.50 ± 12.7027.45 ± 28.320.167PaO~2~, mmHg76.28 ± 14.2580.67 ± 9.7777.47 ± 13.520.614PCO~2~, mmHg40.20 ± 11.9436.24 ± 5.5736.74 ± 4.520.292TLC, % predicted77.17 ± 15.8274.42 ± 10.3777.01 ± 12.700.844DLCO, % predicted53.54 ± 14.0656.62 ± 20.8655.79 ± 8.600.893Chest CT findings at biopsyGround glass opacity15/21 (71.4 %)6/14 (42.9 %)13/20 (65.0 %)0.219Patchy16/21 (76.2 %)10/14 (71.4 %)14/20 (70.0 %)0.899Reticular opacity12/21 (57.1 %)11/14 (78.6 %)12/20 (60.0 %)0.397Bronchiectasis4/21 (19.0 %)5/14 (35.7 %)8/20 (40.0 %)0.315Pleural thickness1/21 (4.8 %)4/14 (28.6 %)3/20 (15.0 %)0.147

Distribution of T lymphocyte subsets among different regions of lung tissue {#Sec12}
---------------------------------------------------------------------------

The distribution of CD4+ T lymphocytes is shown in Fig. [2A](#Fig2){ref-type="fig"}. The number of CD4+ T lymphocytes per 0.1 mm^2^ in the follicle, perivascular, interstitial, and peribronchial regions were 161.4 ± 89.0, 61.4 ± 30.6, 40.9 ± 12.0, and 25.9 ± 14.2, respectively. The numbers of CD4+ T cells decreased gradually in the order of the follicle, perivascular, interstitial, and peribronchial regions. The differences in cell counts between each of two different regions were statistically significant (*p* \< 0.001).Fig. 2**a** Distribution of CD4+ T lymphocytes in different regions of lung tissue. The different in CD4+ cell counts between any two regions were statistically significant (*p* \< 0.001). **b** Distribution of CD8 + T lymphocytes in different regions of lung tissue. CD8+ cell in follicles were much more than those in each of the other three regions (*p* \< 0.001)

The distribution of CD8+ T lymphocytes (Fig. [2B](#Fig2){ref-type="fig"}) was similar to that of CD4+ T lymphocytes. The numbers of CD8+ T lymphocytes per 0.1 mm^2^ in perivascular (47.6 ± 22.7), interstitial (45.7 ± 30.1), and peribronchial (32.5 ± 19.3) regions were not significantly different (*p* = 0.561). The number of lymphocytes in follicles (96.3 ± 58.4) were much greater than those in each of the other three regions (all *p* \< 0.001).

Distribution of CD4+ and CD8+ T lymphocytes among NSIP subtypes {#Sec13}
---------------------------------------------------------------

We analyzed NSIP subtypes as follows: 22 cellular, 28 mixed, and five fibrotic. The distribution of CD4+ and CD8+ T lymphocytes in these subtypes is summarized in Table [4](#Tab4){ref-type="table"}. Perivascular infiltration with CD4+ T lymphocytes was more prominent in patients with the cellular pattern compared with those with the mixed or fibrotic pattern. There was no significant difference in the number of infiltrating CD8+ T lymphocytes among the four anatomical regions.Table 4Distribution of T lymphocytes in patients with different histological patternsTissueCellular NSIP (*n* = 22)Mixed NSIP (*n* = 28)fibrotic NSIP (*n* = 5)*p* valueCD4+ T lymphocytes (number/0.1 mm^2^) Follicle region163.37 ± 89.58159.69 ± 94.36161.93 ± 68.140.990 Perivascular region78.12 ± 34.7949.74 ± 22.4253.10 ± 18.170.003\* Interstitial region40.85 ± 12.6639.54 ± 11.5238.48 ± 13.970.894 Peribronchial region27.53 ± 15.6025.70 ± 13.8220.10 ± 8.840.575CD8+ T lymphocytes (number/0.1 mm^2^) Follicle region123.11 ± 77.8172.62 ± 26.37110.74 ± 36.940.006 Perivascular region57.51 ± 23.4338.91 ± 17.5052.60 ± 29.890.011 Interstitial region57.96 ± 39.8136.26 ± 17.5343.83 ± 18.690.037 Peribronchial region39.11 ± 22.5227.80 ± 16.2729.40 ± 12.500.111

The numbers of CD4+ and CD8+ T lymphocytes cells in the CTD-NSIP (*n* = 21), NSIP-Ab (+) (*n* = 14), and NSIP-Ab (−) (*n* = 20) groups were not significantly different in each of the four anatomical regions (Table [5](#Tab5){ref-type="table"}).Table 5Distribution of T lymphocytes in the CTD-NSIP, NSIP-Ab (+) and NSIP-Ab (−) groupsCTD-NSIP group (*n* = 21)NSIP-Ab (+) group (*n* = 14)NSIP-Ab (−) group (*n* = 20)*P* valueCD4+ T lymphocytes (number/0.1 mm^2^) Follicle region181.5 ± 87.2155.4 ± 110.7144.4 ± 73.10.401 Perivascular region70.2 ± 26.854.5 ± 25.451.2 ± 27.00.061 Interstitial region42.9 ± 12.538.2 ± 10.938.15 ± 12.200.372 Peribronchial region28.8 ± 13.425.6 ± 13.326.3 ± 16.10.989CD8+ T lymphocytes (number/0.1 mm^2^) Follicle region107.9 ± 72.2102.4 ± 26.1107.8 ± 50.90.139 Perivascular region59.5 ± 23.746.6 ± 17.442.7 ± 19.80.115 Interstitial region45.7 ± 23.933.3 ± 19.554.2 ± 39.00.139Peribronchial region36.0 ± 21.630.2 ± 15.730.4 ± 19.40.579

T lymphocyte subsets in lung tissue and improved CT findings {#Sec14}
------------------------------------------------------------

After undergoing therapy for 1 year, 25 patients (20 cellular and five mixed patterns) achieved a 50 % improvement in GGO and reticular opacity (CT-group 1). The lesions of 14 patients (all mixed pattern) decreased between 30 % and 50 % (CT-group 2). The lesions of 14 patients (nine mixed and five fibrotic patterns) were reduced by \<30 % (CT-group 3). The number of CD4+ T lymphocytes in perivascular tissue in the CT-group 1 was significantly greater compared with those of other two CT-groups (76.5 ± 33.9 vs 49.5 ± 17.3, *p* = 0.009; 76.5 ± 33.9 vs 43.9 ± 18.4, *p* = 0.002) (Fig. [3](#Fig3){ref-type="fig"}), but not in the other anatomical regions. There was no correlation between the number of CD8+ T lymphocytes and the improvement HRCT findings.Fig. 3Correlation of T lymphocytes in different regions of tissue and prognosis of NSIP. Group 1: an improvement of ground-glass opacity and reticular opacity over 50 % on HRCT; Group 2: the lesions were still present but decreased between 30--50 % on HRCT; Group 3: the lesions were reduced less than 30 % on HRCT. There is statistical significance of CD4+ lymphocytes perivascular infiltrates among three groups (*p* = 0.001)

T lymphocyte subsets of lung tissue and pulmonary function tests {#Sec15}
----------------------------------------------------------------

Cox multivariate regression analysis revealed that after 12 months of follow-up, FVC was an independent factor for survival (HR, 0.828; 95 % CI, 0.692--0.992; *p* = 0.040) (Additional file [1](#MOESM1){ref-type="media"}: Table S1). There was a marginal correlation of FVC with the number of perivascular CD4 cells (Fig. [4](#Fig4){ref-type="fig"}). Among 55 patients, 21 (11 cellular and 10 mixed patterns) achieved an improvement of FVC \>10 % (FVC-group 1). No correlation between perivascular CD4 infiltration and DLCO at first visit (p=0.642, r=-0.064) (Additional file [2](#MOESM2){ref-type="media"}: Figure s2) and DLCO after 12 months follow up (p=0.134, r=-0.205) (Additional file [3](#MOESM3){ref-type="media"}: Figure S2).

Nineteen patients (eight cellular, nine mixed, and two fibrotic patterns) achieved improved FVC between 10 % and −10 % (FVC-group 2). The FVC values of 15 patients (three cellular, nine mixed, and three fibrotic patterns) decreased greater than −10 % (FVC-group 3). The number of CD4+ T lymphocytes that infiltrated perivascular tissue in FVC-group 1 was significantly greater than those of the other two groups (77.9 ± 31.5 vs 63.0 ± 23.1, *p* = 0.056; 77.9 ± 31.5 vs 46.5 ± 12.5, *p* = 0.001) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 4The relationship between perivascular CD4 infiltration and 12 months Follow-up FVC (*p* = 0.059, r = 0.256)Fig. 5The relationship between CD4 T lymphocytes in perivascular regions of tissue and prognosis of FVC in NSIP patients. There are significant difference among three groups, *p* = 0.001.FVC-Group1 vs FVC-Group2 *p* = 0.056; FVC-Group1 vs FVC-Group3 *p* = 0.000; FVC-Group2 vs FVC-Group3 *p* = 0.054. FVC-group 1: an improvement of FVC over 10 % after 12 months treatment. FVC-group 2: FVC improved between 10 and −10 % after 12 months treatment. FVC-group 3: FVC worsen over −10 % after 12 months treatment

The densities of CD4+ and CD8+ T lymphocytes T that infiltrated other anatomical compartments was not significantly associated with pulmonary function tests.

The number of CD4+ T lymphocytes infiltrating perivascular tissue influences survival {#Sec16}
-------------------------------------------------------------------------------------

Cox multivariate regression analysis considered age, sex, and numbers of CD4+ and CD8+ T lymphocytes infiltrating the lungs, and lung function tests (first visit and after 1 year of follow-up). The results revealed that perivascular infiltration of CD4+ T lymphocytes (HR, 0.939; 95 % CI, 0.883--0.999; *p* = 0.048) was an independent factor for survival (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

The densities CD4+ T lymphocytes infiltrating perivascular tissues of all patients were significantly associated with survival time (*r* = 0.270, *p* = 0.046) (Fig. [6](#Fig6){ref-type="fig"}) compared with those in other anatomical compartments. Further, patients with a much higher density of CD4+ T lymphocytes (≥61 cells/0.1 mm^2^) in the perivascular compartment survived longer (log-rank test, 4.58; *p* = 0.040) (Fig. [7](#Fig7){ref-type="fig"}). The cutoff value was determined using the ROC curve, and the AUC for patients' survival was 0.79 (sensitivity 0.615, specificity 0.710).The densities of CD4+ and CD8+ T lymphocytes infiltrating other anatomical compartments were not significantly associated with survival time.Fig. 6CD4+ T lymphocytes perivascular infiltration were closely related to survival time in NSIP patients. Correlation coefficients were calculated using the Spearman rank methodFig. 7Kaplan-Meier survival curve for 55 NSIP patients grouped by the cell density of CD4 in small vessel region. Green line: ≥61 cells/0.1 mm2. Blue line: \< 61 cells/0.1 mm2. There is a significant difference (log-rank test: 4.58, *p* = 0.04) between the groups

The most important finding of the present study was that the number of CD4+ T lymphocytes that infiltrated perivascular tissue correlated significantly with the prognosis of NSIP.

Immunohistochemical analyses revealed the T lymphocyte subsets infiltrated not only lymphoid follicles and interstitial regions, but perivascular and peribronchial regions as well, which is consistent with the findings of our previous study \[[@CR7]\]. In this study, we did not detect a significant difference in T lymphocyte density among cellular, mixed, and fibrotic patterns among the same tissues analyzed here. The small number of patients with the fibrotic pattern might account for these findings, although we show here that there were more lymphocytes in patients with the cellular than with the fibrotic pattern. In contrast, in the present study, we found a correlation between the infiltration of perivascular tissue with CD4+ T cells with prognosis.

The predictors of prognosis of patients with ILD are the results of the pulmonary function test \[[@CR18]--[@CR20]\] and all-cause mortality \[[@CR27]--[@CR31]\]. In the present study, we combined them \[[@CR29]\] to analyze perivascular CD4+ T lymphocyte infiltration and clinical prognosis. FVC consistently predicts the mortality of patients with IPF \[[@CR17]--[@CR20], [@CR32]\] and is considered the best marker of chronic disease progression. FVC data now serve as the preferred primary endpoint in trials of therapies IPF \[[@CR33]\].

In the present study, we show that FVC was an independent predictor of survival, which is consistent with the results of previous studies \[[@CR32], [@CR34]--[@CR37]\]. When we classified patients according to the change of FVC after the 12-month follow-up, we found that higher numbers of perivascular CD4+ T lymphocytes correlated with improved FVC.

In the present study, all-cause mortality was 23.6 %. Cox multivariate regression analysis revealed that perivascular CD4+ T lymphocyte infiltration was an independent predictor of survival. Survival time correlated with the number of perivascular CD4+ T lymphocytes. Patients with higher numbers of perivascular T lymphocytes in the perivascular region have a better prognosis.

The accumulation of T lymphocytes in tissue is considered a cell-mediated immune reaction to bodily injury \[[@CR38]\], particularly in patients with immune dysfunction \[[@CR39]\]. The accumulation of perivascular CD4+ T lymphocytes occurs in patients with cutaneous lichen planus \[[@CR40]\] and in the muscle tissue of patients with dermatomyositis \[[@CR41]\]. Some studies found that T cells might be involved in the pathogenesis of interstitial lung disease. For example, the levels of CXCL9, CXCL10, and CXCL11 in bronchoalveolar lavage fluid indicate that lung fibroblasts induce a Th1-type immune response in patients with NSIP \[[@CR42]\].

In an animal model of lung injury, perivascular CD4+ T lymphocytes accumulate in lung tissue \[[@CR43], [@CR44]\]. In patients with interstitial pneumonia caused by graft-versus-host disease, interstitial pneumonitis develops primarily from the dissemination of perivascular CD4+ T lymphocytes infiltrates \[[@CR45]\]. Immunosuppressive agents such as cyclophosphamide suppress inflammation caused by perivascular T lymphocytes by reducing the T lymphocyte population and ameliorating T lymphocyte function \[[@CR46]\]. These findings, taken together with those of the present study, suggest that perivascular infiltration of CD4+ T lymphocytes contributes to the pathogenesis of NSIP. If CD4+ T cells are involved in ILD, treating patients with anti-T cell-specific immunosuppressants such as FK506 and anti-TNF-α antibodies may be justified. For example, patients with ILD, particularly those with CTD-ILD, respond to these agents, \[[@CR47], [@CR48]\].

It is very unlikely that lung biopsies will be performed solely to count T-cells when pulmonary function tests and other less invasive measures are available. The implication of our findings related to therapy is that they provide an answer to the question of why anti-T cell treatment is beneficial for patients with ILD.

We recognize that our study is limited by its retrospective design, and B lymphocyte and other inflammatory cells were not investigated. However, to our knowledge, this is the first study to evaluate the relationship between perivascular infiltration of CD4+ T cells and the prognosis of patients with NSIP.

In conclusion, we show here that perivascular infiltration of CD4+ T cells correlated significantly with prognosis and survival. The underlying mechanisms require further study.

Additional files {#Sec17}
================

Additional file 1:**Table S1.** The prognostic factors study with multivariate analysis. (DOCX 406 kb) Additional file 2:**Figure S1.** The relationship between perivascular CD4 infiltration and DLCO (*p* = 0.642, r = −0.064). (PPT 98 kb) Additional file 3:**Figure S2.**The relationship between perivascular CD4 infiltration and 12 months follow-up DLCO (*p* = 0.134, r = −0.205). (PPT 43 kb)
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